Study of the involvement of the gut microbiota in the pathophysiology and treatment effect of patients with unresectable hepatocellular carcinoma.

Not Applicable

• Conditions: Hepatocellular carcinoma

• Registration Number: JPRN-UMIN000042709
• Lead Sponsor: Kurume university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-10
• Last Update Posted: 17 October 2023
• Study Completion: 2025-03-15

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

A) Patients with unresectable advanced hepatocellular carcinoma. 1. Patients with decreased hepatic reserve (Child-Pugh class C). 2. Patients with intractable ascites. 3. Patients judged by the principal investigator and the research coordinator to be inappropriate as research subjects. B) Patients with liver cirrhosis. 1. Patients with decreased hepatic reserve (Child-Pugh class C). 2. Patients with intractable ascites. 3. Patients judged by the principal investigator and the research coordinator to be inappropriate as research subjects. 4. Patients who have been treated with antibacterial drugs due to the appearance of hepatic encephalopathy. C) Healthy person. 1. Those who are pregnant or breastfeeding, or those who are judged by the principal investigator and the research coordinator to be inappropriate as research subjects.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of the composition of the gut microbiota in patients with hepatocellular carcinoma, patients with cirrhosis, and healthy individuals.

Secondary Outcome Measures

Name	Time	Method
Cytokine and chemokine concentrations in the blood of patients with hepatocellular carcinoma and the ratio of tumor immune-related cells in the blood.